Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes resulting from dividend reinvestment.
Material Changes
On January 21, 2016, GSK reported increases in the notional interests of specific PDMRs in Ordinary Shares. These increases resulted from the reinvestment of dividends paid on January 14, 2016, under the GlaxoSmithKline Deferred Investment Award Programme. The transaction price was 1372.50 pence per Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the specific share counts acquired by PDMRs through dividend reinvestment.
- Confirm the transaction price of 1372.50 pence per Share against market data for January 2016.
- Review the full list of PDMRs involved: Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.